Shashikanth Ponnala
Overview
Explore the profile of Shashikanth Ponnala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Heide C, Campeiro J, Ruigrok E, van den Brink L, Ponnala S, Hillier S, et al.
EJNMMI Res
. 2024 Dec;
14(1):125.
PMID: 39718718
Background: Fibroblast activation protein (FAP) is an attractive target for cancer theranostics. Although FAP-targeted nuclear imaging demonstrated promising clinical results, only sub-optimal results are reported for targeted radionuclide therapy (TRT)....
2.
Kelly J, Jeitner T, Ponnala S, Williams Jr C, Nikolopoulou A, DiMagno S, et al.
Mol Imaging Biol
. 2021 Mar;
23(5):686-696.
PMID: 33721173
Purpose: Fibroblast activation protein-α (FAPα) is uniquely expressed in activated fibroblasts, including cancer-associated fibroblasts that populate tumor stroma and contribute to proliferation and immunosuppression. Radiolabeled FAPα inhibitors enable imaging of...
3.
Kelly J, Ponnala S, Amor-Coarasa A, Zia N, Nikolopoulou A, Williams Jr C, et al.
Mol Pharm
. 2020 Apr;
17(6):1954-1962.
PMID: 32286841
The application of small molecules targeting prostate-specific membrane antigen (PSMA) has emerged as a highly promising clinical strategy for visualization and treatment of prostate cancer. Ligands that integrate the ability...
4.
Qu W, Hu B, Babich J, Waterhouse N, Dooley M, Ponnala S, et al.
Nat Commun
. 2020 Apr;
11(1):1736.
PMID: 32269227
Carbon-11 (C) is one of the most ideal positron emitters for labeling bioactive molecules for molecular imaging studies. The lack of convenient and fast incorporation methods to introduce C into...
5.
Bhupathiraju N, Younes A, Cao M, Ali J, Cicek H, Tully K, et al.
Org Biomol Chem
. 2019 Jul;
17(28):6866-6871.
PMID: 31268109
The bifunctional ligand p-SCN-Bn-HOPO, which has four 1,2-hydroxypyridinone groups on a spermine backbone with an isothiocyanate linker, has been shown to be an efficient and stable chelator for Zr(iv) and,...
6.
Amor-Coarasa A, Kelly J, Singh P, Ponnala S, Nikolopoulou A, Williams Jr C, et al.
Molecules
. 2019 Apr;
24(8).
PMID: 31022852
Determining chemokine receptor CXCR4 expression is significant in multiple diseases due to its role in promoting inflammation, cell migration and tumorigenesis. [Ga]Pentixafor is a promising ligand for imaging CXCR4 expression...
7.
Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams Jr C, DiMagno S, et al.
J Nucl Med
. 2018 Dec;
60(5):656-663.
PMID: 30552199
Despite significant gains in the treatment of metastatic castration-resistant prostate cancer by radioligands targeting prostate-specific membrane antigen (PSMA), 30% of patients never respond to therapy. One possible explanation is insufficient...
8.
Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams Jr C, Thiele N, et al.
J Nucl Med
. 2018 Nov;
60(5):649-655.
PMID: 30413660
Promising biochemical responses to Ac-prostate-specific membrane antigen (PSMA) 617, even in patients who are refractory to β-particle radiation, illustrate the potential of targeted α-therapy for the treatment of metastatic castration-resistant...
9.
Amor-Coarasa A, Kelly J, Ponnala S, Nikolopoulou A, Williams Jr C, Babich J
Molecules
. 2018 Oct;
23(10).
PMID: 30304795
Emerging interest in extending the plasma half-life of small molecule radioligands warrants a consideration of the appropriate radionuclide for PET imaging at longer time points (>8 h). Among candidate positron-emitting...
10.
Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams Jr C, Schlyer D, et al.
Eur J Nucl Med Mol Imaging
. 2018 Apr;
45(11):1841-1851.
PMID: 29623376
Purpose: Treatment of late-stage prostate cancer by targeted radiotherapeutics such as I-MIP-1095 and Lu-PSMA-617 has shown encouraging early results. Lu-177 is preferred to I-131 in clinical settings, but targeted radioligand...